

Hong Kong Biomedical Cluster and Leading IPO Center in Asia

Senior Manager, Innovation & Technology
Gregory Rall
May 2022 Basel

Invest**HK**



InvestHK: a Government Agency to Help Companies Grow



Vision: To strengthen Hong Kong's status as the leading international business location in Asia

Mission: To promote and attract foreign investment to Hong Kong by assisting overseas and Mainland companies in setting up business activities in Hong Kong

Execution: To offer free advice and services to support companies from the planning stage right through to the launch and expansion of their businesses

We offer sector-specific knowledge and expertise to our clients



Business & Professional Services



Creative Industries



Consumer Products



Financial Services



Tourism & Hospitality



Transport & Industrial



Innovation & Technology



FinTech



Start-ups



We have Global Presence and Bridging to Major Markets in Asia via our Hub

Our global presence in 31 locations



Reaching Key Markets via Hong Kong

50% world's population within 5 hrs flight.



Hong Kong's Unique Competitive Advantages in Doing Business

Excellent Accessibility



- Hong Kong Int'l airport: ~120 airlines; 220 destinations; half world population within 5-hr flight
- HK-Zhuhai-Macao Bridge
- Guangzhou-Shenzhen-HK Express Rail Link

Simple and Low Tax System

16.5%
Profits above HK\$2M


NO

- VAT/GST/Sales tax
- Capital Gains tax
- Withholding tax on investments
- Estate duty
- Global taxation
- Wine duty

8.25%

First HK\$2M of profits

Capital Fund Raising



- Ranked #1 IPO fund raising globally in 6 of the past 10 years
- 2nd largest IPO center globally for Biotech after New York

Leading IP System

Registration

Protection

Asset Management

- Dual Patent Systems: Re-registration & Original Grant Patent
- WIPO: Multiple country registration
- Robust legal structure and jurisdiction to support HK as a litigation & arbitration hub
- IP trading hub (low tax rate, deduction on patent expenditure)

Greater Bay Area



POPULATION

~71 million
> UK, Italy

GDP

~US\$1.6 trillion
~ Australia, Spain

Vibrant Startup Ecosystem

- Strong network of incubators and accelerators
- A pool of experienced angels and venture capitalists
- A range of government backed programmes
- Community of startups

Life Science

Biomedical Development in Hong Kong

Basic Research

Pre-clinical

Clinical Trial

Commercialisation / Sales & Business Development

Researcher, Entrepreneur, Univ. Spin-off, Tech Venture (Startup, Scale-up), Pharmaceutical Companies



Academic & Research



Government, Incentives



Private Sectors




Healthcare System

HKGI Hong Kong Genome Project
 香港基因組中心
Hong Kong Academy of Sciences 香港科學院
HKSTP Ventures Corporate Venture Fund
 香港科技大學 THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY
 香港中文大學 THE CHINESE UNIVERSITY OF HONG KONG
 香港大學 THE UNIVERSITY OF HONG KONG
 CityU City University of Hong Kong

HKSTP Incu-Bio: 4 yrs HK\$6M
LSGM Logistics and Supply Chain Management Research Institute
ASTRI Advanced Technology Research Institute
hkpc High Performance Computing Center
 Biomedical Technology Support Centre
 Healthcare Device Innovation Hub
 Biobank, GLP, GMP
 Technology Transfer Offices


Globally recognized & top-notch investigators
 Two global well-known medical schools



Health@InnoHK Hub for Global Research in Healthcare	I&T Venture Fund (ITVF) HK\$2B Fund Size 1 Gov: 2 VC	Enterprise Support Scheme (ESS) HK\$10M R&D Projects on 1:1 Matching Basis	Partnership Research Program (PRP) 50% Research cost subsidized
Research Talent Hub (RTH) Subsidies for hiring up to 4 R&D talents	Tech Start-up Support Scheme for University (TSSSU) HK\$8M per univ.	R&D Cash Rebate Scheme (CRS) 40% Rebate on R&D	Tax Deduction for R&D 300% For 1st HK\$2M, 200% For remaining

Incubator/ Accelerator: **HACK ASIA**, **EUREKA NOVA**, **HK LAB**
Betatron, **brinc**, **WHub**, **NORDIC INNOVATION HOUSE**
 Contracted research

Contract Development & Manufacturing Outsource (CDMO)
 Toxicology in Shenzhen



Global Contract Research Organisations (CRO)



- 18A Biomedical Listing
 - Simple & Low Tax Rate
 - Common Law System
 - Robust IP Protection
 - Professional Services
 - Free flow of People, Trade & Currency
 - GBA Facilitation Measures (relax human samples)
- HKEX** 香港交易所
-




- Smart Hospital:
- 5G enabled
 - Telehealth
 - Telemedicine
 - Robots
- Pharma Revolution:
- DNA analytics
 - Genomics
 - Traditional Chinese Medicine

Note (1) – NMPA National Medical Products Administration

Hong Kong Has a Well-Structured Dual-Track Healthcare System

Efficient dual-track healthcare system⁽¹⁾




- (1) Hong Kong was ranked #1 the most efficient medical care system in the world in 2018 by Bloomberg. The Electronic Health Record Sharing System (eHealth) provides a role-based access control patient record platform to facilitate free-of-charge electronic health records sharing for all members of the public.
- (2) The Food and Health Bureau (FHB) is responsible for forming policies and allocating resources for running of Hong Kong's health services.
- (3) The Department of Health (DoH) is the Government's health adviser and agency to execute healthcare policies and statutory functions.
- (4) The Hospital Authority (HA) is a statutory body providing public hospitals and related services to citizens of Hong Kong. It offers medical treatment and rehabilitation services to patients through hospitals, day hospitals, specialist clinics, general out-patient clinics.
- (5) Private Health Care includes a number of private hospitals and medical services. DoH regulates all private hospitals and medical clinics registered under the Medical Clinics Ordinance (Cap. 343). DoH monitors their compliance by conducting inspections. All Western medicine practitioners practicing in Hong Kong have to register with the Medical Council of Hong Kong (MCHK) to ensure professional standards are warranted.

Note (a) – MDACS Medial Device Administrative Control System

Hong Kong is a Leading Clinical Trial Center in Asia

Simple and Transparent Regulatory Framework Aligns with western countries and use English language



High Quality Data Accredited by FDA & NMPA

Clinical trial data in 4 hospitals⁽¹⁾ is simultaneously recognized for drug registration by various regulatory bodies including FDA, EMA and NMPA⁽²⁾

Two Phase I Clinical Trial Centers accredited by NMPA⁽²⁾



Queen Mary Hospital



Prince of Wales Hospital

Note (1) – QMH, PWH, HKEH, HKSH
Note (2) – NMPA National Medical Products Administration

Globally Recognised and Top-Notch investigators



Globally recognised well-known Principal Investigators (PI)⁽¹⁾ in:

Two global well-known medical schools

Gastroenterology

Hepatology

Cardiology

Oncology

Infectious Disease

Endocrinology



A network of Global and Regional CROs

Foreign Clinical Trial Data + Bridging Study

Global / Regional Clinical Trials

Full China Clinical Trial After FDA/EMA Approval



Hong Kong is a Leading Clinical Trial Hub in Asia

Hong Kong's unique propositions: Speed, Quality and Availability of Qualified Persons

Medical Innovation

- Collaboration with global institutes and community for medical research (e.g. Karolinska Institute in Hong Kong)
- Top-notch academic resources and research facilities available
- Government's commitment including funding and incentives (e.g. InnoHK)



Clinical Trial Planning / Approval

- Simple and transparent clinical trial registration approval framework
- Experienced and extensive network of global CROs in Hong Kong
- Globally recognized and credible top-notch investigators
- Bilingual spoken English and Chinese language and multi-cultural



Globally recognised well-known Principal Investigators (PI) in, for examples: Oncology, Hepatology, Endocrinology, Cardiology, Gastroenterology, Infectious Disease



Clinical Trial Execution

- Four Hong Kong hospitals⁽¹⁾ are accredited for Phase I clinical trial by China NMPA⁽²⁾
- High quality of clinical data accredited by global regulatory bodies (e.g. FDA⁽³⁾, EMA⁽⁴⁾)
- High quality and well-equipped hospitals and laboratory facilities for early phase clinical trials
- Speedy patient recruitments (e.g. Asian patients and niche diseases)



Queen Mary Hospital



Prince of Wales Hospital

(1) The four hospitals are: The Clinical Research Management Office at The Chinese University of Hong Kong (CUHK-CRMO); The Clinical Trial Centre at the University of Hong Kong (HKU-CTC); The Hong Kong Sanatorium Hospitals oncology department, The Hong Kong Eye Hospital

(2) NMPA - National Medical Products Administration


(3) FDA – US Food and Drug Administration

(4) EMA – European Medicines Agency

Healthcare Services Development in Hong Kong

Prevention

The government is committed to Primary Care by establishing District Health Centers which leverages on medical-social collaboration to provide primary healthcare services.




Diagnostics

Private sectors are developing diagnostics technology for screening of diseases at their early stage for early intervention. For example:

Take2 is a healthcare technology company based in Hong Kong.

Focusing on the development and commercialization of technologies to provide the early detection of Nasopharyngeal cancer (NPC)



Treatment

Day procedural centres and specialty clinics established to provide treatment for less acute cases from hospitals. For examples:



Established in 2015 to provide diversified medical assessment & treatment services.

Including screening, imaging/ diagnosis and interventional assessment.



The Central Surgery
中環外科

Established in 2018 to offer day surgery at easily accessible locations



Rehabilitation

Demand for private specialist care is rising in Hong Kong due to ageing population. Rehabilitation center has been offered by the private sector. For example:



Established in 2018, offering multi-disciplinary medical services.

It provides a full range of services from wellness and prevention, diagnosis, treatment, to rehabilitation. For rehabilitation, each patient is provided by a multidisciplinary allied health team coordinated by a dedicated health consultant.



Neurological Rehabilitation Centre

DNA Analytics in Hong Kong (and breaking news on Genomics-Sanomics merger)

Invitation



Merger Signing Ceremony

Becoming an integrated oncology diagnostic powerhouse in Asia

The merger brings two leaders in oncology diagnostics together. The newly formed Asian powerhouse will bring complete global cancer diagnostics solutions to patients, medical professionals, pharmaceutical companies, and researchers.

You are cordially invited to witness and celebrate the signing ceremony for the merger between ACT Genomics and Sanomics, with details as follows:

Date: November 22, 2021 (Monday)

Reception: 10:30 a.m.

Ceremony: 11:15 a.m.

Venue: INNO 2, 2/F, Building 17W, Science Park West Avenue, Hong Kong Science Park, Pak Shek Kok, New Territories

Guests of Honour:

- Mr. Alfred Sit, JP** Secretary for Innovation and Technology, Innovation and Technology Bureau
- Ms. Annie Choi, JP** Permanent Secretary for Innovation and Technology, Innovation and Technology Bureau
- Dr. Sunny Chai, JP** Chairman, Hong Kong Science and Technology Parks Corporation
- Mr. Albert Wong** Chief Executive Officer, Hong Kong Science and Technology Parks Corporation
- Mr. Eugene Hsia** Chief Corporate Development Officer, Hong Kong Science and Technology Parks Corporation
- Professor John Kao** Head of Institutes of Translational Research, Hong Kong Science and Technology Parks Corporation

Officiating Guests:

- Professor Tony Mok** Chairman, Sanomics Holdings Limited
- Mr. Victor Chan** CFO, ACT Genomics Holdings Company Limited
- Mr. Stanley Sy** CEO, Sanomics Holdings Limited
- Dr. Kirsty Lee** COO, Sanomics Holdings Limited

Dress Code: Business Attire



ACT Genomics is a molecular diagnostic company that helps biopharma drug development through biomarker discovery, patient stratification, and comprehensive cancer molecular analysis.

ACTHRD™
DNA Repair Gene Testing

ACTBRCA®
BRCA1/2 Gene Testing

ACTCerebra™
Brain Metastases Gene Testing

ACTOnco® +
Comprehensive Genomic Profiling

ACTDrug® +
Targeted Genomic Profiling

ACTFusion™
Fusion Gene Testing



Founded in 2015, specialises in providing liquid biopsy and tissue based genetic diagnostics for cancer patients, helping doctors decide personalized cancer solutions.

ELITE



Enterprise Support Scheme (ESS)



Innovation and Technology Scholarship Internship Programme



Technology Voucher Programme (TVP)



Postdoctoral Hub (PhD)



SME Export Marketing Fund



AI for Drug Discovery and Diagnostic in Hong Kong



BrainNow is founded by a local team of doctors and engineers at the Chinese University of Hong Kong, currently under incubation in HKSTP

BrainNow develops clinically applicable computer-aided design (CAD) software tool leveraging AI analytics for diagnoses of dementia and other neurological diseases.




Insilico Medicine, founded in 2014, setting up HQ in HK targeting pharmaceutical industry in Greater China

Insilico Medicine uses AI and deep-learning techniques to analyse how a compound will affect cells and what drugs can be used to treat the cells; making it an alternative to animal testing for R&D programs in the pharmaceutical industry.



Insight is incubated by the Medical Image Analysis laboratory at the CUHK. It was founded by a group of professors and PhDs from CUHK. The company has been voted as one of the top 50 AI companies in China in 2017.

Insight focuses in developing medical image analysis software together with large-scale platforms for automated processing of medical images.



Chest X-ray, AI assisted diagnosis system



Cervical liquid-based cell AI screening system

Pharma Revolution in Hong Kong

In line with global pharma revolution, Hong Kong attracts local and global talents in stem cell innovation.



Karolinska Institutet (KI)

Ming Wai Lau Centre for Reparative Medicine (MWLC), set up in 2016, to accelerate research in stem cell biology, biomedical engineering, biotechnology and regenerative medicine at KI.



Novoheart

Specializes in the research stem cell with proprietary bioengineered human heart constructs. It revolutionizes drug discovery and development of heart therapeutics.



The "human heart-in-a-jar" model

Invitrocue



Specializes in developing 3D cell-based models derived from liver and tumour tissues. The company recreates cancer cells (organoids) that can be cultured in laboratories for testing against a panel of cancer drugs.



Hong Kong Genome Project (HKGP)

Hong Kong Genome Project



HK\$1.2bn DNA **Whole Genome Sequence** project to:

- Build a large-scale database of anonymized genomic and clinical data to enhance the **clinical application** of genomic medicine and to facilitate **scientific research**
- Build infrastructure and protocol for genetic and genomic testing
- Standardize format and bioinformatics pipelines

Pilot Phase

(Target 1 year, mid 2022 completion)

- 2,000 cases (5,000 genomes)
- Target: undiagnosed disorders cancers with hereditary components

Main Phase

(Target 3-4 years completion)

- 18,000 cases (45,000 genomes)
- Target: other diseases, research cohorts

Hong Kong Genome Institution (HKGI) was incorporated in May 2020 to implement this HKGP with partnership with other stakeholders.

Key Stakeholders

Department of Health
(DoH)

Hospital Authority
HA

Universities
HKU, CUHK

Private Hospitals
Local labs

Key Benefits

Patient
Benefits

Business
Benefits

Talent
Development

Data Access Tier

1 Identifiable, individual-level genomic & clinic data

Clinicians of partnering centres; access to patient WGS

2 De-identifiable, individual-level, linked genomic and clinical data

Research institutes to access datasets; granted on a project-by-project basis

3 Anonymous, aggregated

Designated facilities; access only to anonymous analysis results

European Talents in Hong Kong

European Biomedical Innovators calling the Hong Kong Science Park their home in Asia: Miltenyi Biotec (Germany), InvivoGen (France) and Medicus AI (Austria)

Case Study



An Excellent Environment for Healthtech Solutions

Miltenyi Biotec believes that combining science, diagnostics and engineering can lead to breakthroughs for complex diseases.

“The very high level of scientific education and expertise is a major reason why Hong Kong is of strategic importance for our business in Asia.”

Ken Ooi
General Manager, Hong Kong
Miltenyi Biotec



The pandemic has demonstrated the need for new medical solutions. Doctors and scientists are eager to stay one step ahead of virus mutations. German cellular research and therapy pioneer Miltenyi Biotec understands that manufacturing cellular therapies requires a different set of skills from traditional ones based on chemical molecules. To achieve excellent results for its customers, it adopts a three-pronged strategy of deep scientific understanding, cutting edge diagnostics and advanced genetic engineering to address complex diseases such as cancer.

Strong Local Support

“Miltenyi Biotec offers a body of expertise ranging from basic science to new technology development and translation into new therapies,” explained Ken Ooi, Miltenyi Biotec’s General Manager for Hong Kong. He described Hong Kong Science and Technology Park (HKSTP) as instrumental to why the city was chosen as Miltenyi Biotec’s regional centre for research and development. “We are thankful for the profound support HKSTP provided during the recent set up of our new office,” he said. “Leveraging HKSTP’s world class infrastructure and ecosystem helps to make our innovative solutions for gene and cell therapy available to patients and customers in Hong Kong, Mainland China and the APAC region.”

Setting up an R&D office during the height of a global pandemic presented its own set of challenges. “Face to face training of new staff could only happen while following strict rules. In the midst of global travel bans and quarantine restrictions, it was necessary to have effective ways of communicating with local staff and customers through innovative technology. Our Hong Kong customer specific content website aims for stronger customer engagement with less in-person activity. Its informative content allows us to market ourselves in a considerably more effective way,” Ooi said.

Excellence in Scientific Education

The Hong Kong office was established as a strategic hub for servicing Miltenyi Biotec’s Greater China market. Ooi acknowledged that the city boasts robust infrastructure and solid access to outstanding talent and biomedical know-how. “Hong Kong offers a very capable and stable environment,” Ooi stated. “The very high level of scientific education and expertise is a major reason why Hong Kong is of strategic importance for our business in Asia. There is huge potential in making our technology available to universities in Hong Kong and the Greater Bay Area, or establishing our solutions across hospitals in the region for patient care.”

Miltenyi Biotec

- Established in 1989 and headquartered in Germany, Miltenyi Biotec specialises in biomedical research that enables cell and gene therapy
- Its Hong Kong subsidiary acts as a regional research and development centre, supporting teams in the Greater Bay Area via Guangzhou, Beijing, Shanghai and other key Asia-Pacific cities

© miltenyibiotec.com
© Copyright InvestHK Hong Kong, January 2022. All rights reserved.

InvivoGen (France)

InvivoGen is a provider of biological tools for research in cellular and molecular biology.



Medicus AI (Austria)

Medicus AI designs and develops an artificial intelligence (AI) based enterprise and app platform that bring meaning to health data.





[VIEW ALL NEWS](#) →

MODERNA ANNOUNCES PLAN TO EXPAND FOOTPRINT IN ASIA WITH FOUR ADDITIONAL SUBSIDIARIES

FEBRUARY 15, 2022

[DOWNLOAD](#)

Announcement reinforces Moderna's commitment to Asia and vision as a global commercial enterprise


New subsidiaries to be established in Malaysia, Taiwan, Singapore, and Hong Kong; providing local presence to support the delivery of mRNA vaccines and therapeutics

CAMBRIDGE, MA / ACCESSWIRE / February 15, 2022 / Moderna, Inc., (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced plans to expand its commercial network across Asia with the addition of four new subsidiaries in Malaysia, Taiwan, Singapore, and Hong Kong. This expansion comes as the Company continues to scale up the manufacturing and distribution of its COVID-19 vaccine and future mRNA vaccines and therapeutics.

Fundraising / Capital

Hong Kong is the World-Leading Market for Capital Fund Raising

HK is a leading IPO fund raising platform in term of market size



Source: HKEX (2010-2019); KPMG (2020 estimated)

Why listing in Hong Kong?

Accessibility

- Access to global capital, global investors, top biz institutions & corporates
- Close proximity to Mainland China

Sustainability

- The world's no. one IPO market for many years in the past
- Strong and robust secondary market

Credibility

- World-class legal regime, listing platform, financial center, banking & audit infrastructure
- Conform to int'l standards

Adaptability

- Chapter 18A – pre-revenue & pre-profit scheme for biotech companies
- Weighted Voting Rights for new economy companies

Hong Kong is 2nd Largest IPO Center for Biomedical After New York

Conventional Listing Requirements

Financial Requirement:

Profit Test

- Last year profit \geq HK\$20m or (US\$2.6m)
- Aggregated profit of two preceding years \geq HK\$30M or (US\$3.8m) in aggregated
- Market cap \geq HK\$500m or (US\$64.1m)

OR

Market Cap/ Revenue Test

- Market cap \geq HK\$4b or (US\$513m)
- Revenue of the most recent audited year \geq HK\$500m or (US\$64.1m)

OR

Market Cap/ Revenue/ Cashflow Test

- Market cap \geq HK\$2bn or (US\$256m)
- Revenue of most recent audited financial year \geq HK\$500m or (US\$64.1m)
- Aggregated positive cash flow from operating activities for 3 preceding financial years \geq HK\$100m or (US\$12.8m)

Management Control:

- Ownership continuity and control for 3 financial years

Public Float:

- Minimum of 25% public float
- If mkt cap \geq HK\$10bn or (US\$1,282m), may lower to 15%

Biotech Chapter 18A Listing Requirements

2nd largest IPO center globally for biotech companies after New York

	2017	2018	2019	2020
No. of 18A Listed Companies	None	5	14	21
Total IPO Fund Raised (HK\$bn)	None	18.5	34.5	53.6



Product regulated by competent authority

FDA, NMPA, EMA



Past Concept Stage

Completed FDA Phase I clinical trial and receive no objection to commence Phase II (or later)



Market Cap \geq HK\$1.5bn (or US\$0.2bn)

Meaningful investment from at least one sophisticated investor

IPO Samples – Listed Non-18A Companies

Especially
Tigermed, a
Chinese CRO,
performed good.

Market Highlights Achievements Advantages Requirement & Process

Biotech- Listed Non-18A Companies

- ✓ Both 18A and non-18A listings have gained momentum since the initial launch of Biotech Chapter in April 2018
- ✓ Biotech Chapter has attracted sub-sector diversification.

Stock Code	Company Name	Listing Date	Fund Raised (HK\$m)	MC (HK\$m)	6M ADT (HK\$m)	Sector	Product Stage ¹
3347	Hangzhou Tigermed - H Shares	7/8/2020	10,706.51	13,586.56	464.39	Biotechnology	N/A
9906	Honliv Healthcare	13/7/2020	315.00	1,104.00	5.88	Medical & Aesthetic Services	N/A
9989	Shenzhen Hepalink - H Shares	8/7/2020	4,049.74	3,569.93	156.52	Pharmaceuticals	N/A
6078	Hygeia Healthcare	29/6/2020	2,553.00	25,214.40	139.89	Medical & Aesthetic Services	N/A
9997	Kangji Medical	29/6/2020	3,597.79	31,430.41	277.33	Medical Devices	N/A
3390	Tycoon Group	15/4/2020	286.71	800.00	2.68	Pharmaceuticals	N/A
3759	Pharmaron Beijing - H Shares	28/11/2019	5,293.05	13,803.70	05.79	CRO/CDMO	N/A
1501	Shanghai Kindly Medical - H Shares	8/11/2019	956.80	2,806.00	12.75	Medical Devices	N/A
1846	EuroEyes International	15/10/2019	684.26	1,975.40	5.50	Medical & Aesthetic Services	N/A
1931	IVD Medical	12/7/2019	1,023.54	3,537.11	4.41	Medical Devices	N/A
1951	Jinxin Fertility	25/6/2019	3,507.31	26,578.75	179.84	Biotechnology	N/A
3692	Hansoh Pharmaceutical	14/6/2019	9,040.44	217,522.93	199.26	Pharmaceuticals	N/A
1521	Frontage Holdings	30/5/2019	1,606.11	8,112.78	41.00	CRO/CDMO	N/A
1073	Viva Biotech	9/5/2019	1,553.56	17,224.91	140.20	CRO/CDMO	N/A
1827	Miracor Enterprises	18/2/2019	-	232.00	0.03	Medical & Aesthetic Services	N/A
2359	WuXi AppTec - H Shares	13/12/2018	8,282.09	35,234.92	200.54	CRO/CDMO	N/A
1652	Fusen Pharmaceutical	11/7/2018	416.00	2,798.14	1.47	Pharmaceuticals	N/A
1763	China Isotope & Radiation - H Shares	6/7/2018	1,727.33	2,231.13	11.89	Pharmaceuticals	N/A
3613	Beijing Tong Ren Tang	29/5/2018	-	7,433.45	15.91	Pharmaceuticals	N/A
1833	Ping An Healthcare and Technology	4/5/2018	8,773.16	120,604.24	712.57	Medical & Aesthetic Services	N/A

1. Clinical stage of the drugs is based on the time when the company filed A1 submission with SEHK.
2. Source: IICEX, Bloomberg, as at 31 Aug 2020



Prenetics as SPAC example


Prenetics, from Hong Kong, is a genetic and diagnostic health testing company that helps identify health risks with the use of a DNA sequencing technology.

Source: FEW –
Female
Entrepreneurs
Worldwide





Greater-Bay-Area (GBA)

GBA City's Demographics



GBA – Asia Powerhouse



In China for China

- 1.4bn population
- Dual circulation



Asian Markets

- 50% world pop. within 5 hrs flight
- Regional Comprehensive Economic Partnership (RCEP)

HKSTP

Hong Kong Science Park – The International Innovation & Technology Park

- Established in 2002
- 400,000 m² R&D Office & Lab Space
- ~900 Tech Enterprises, ~13,000 Working Population
- Leading Technology Incubator with ~400+ Start-ups



HSITP

Illustrative Plan

– Hong Kong Shenzhen Innovation & Technology Park (HSITP)



Hong Kong – Shenzhen Innovation & Technology Park (HSITP)



HSITP: Phased Development

Phased Development

Phase One GFA about **540,000m²**



31 buildings

Phase Two GFA about **660,000m²**



36 buildings



67 buildings

Including dry-lab, wet-lab, office, teaching facilities, exhibition area and ancillary facilities

6 Focus Areas



Healthcare Technologies




Big Data / A.I.



Robotics



New Materials



Micro Electronics



FinTech

3 Core Functions

The Park will be a place for close collaboration among industry, academia and R&D sector where R&D, prototyping, product design, proof of concept, test-bed and other high value-added activities will be carried out



Research and Development



Cultural and Creative Industries



Higher Education

Summary

We Help Throughout the Entire Customer Journey



Information to aid planning & evaluation

- I&T industry advice and opportunities
- I&T regulation & certification
- Government funding schemes
- Business incorporation procedures
- Tax and business regulation
- Visa programmes
- Employment legislation



Business support facilitation

- Support & assist with business licenses, visa applications, bank account opening, funding applications
- Advice on living and working in Hong Kong – housing, healthcare, schooling, office location & rental, and networking



Networking events & business introduction

- Arrangement of visits programmes to ecosystem partners (e.g. Science Park, Cyberport, research institutes), professional associations, government officials and departments
- Introduction to business contacts
- Public relation services




PR & marketing support, business networking

- Ongoing aftercare services
- Industry and market trends updates
- Business introduction and networking
- Public relation services
- Advise on R&D grants and other government schemes



We Connect the Dots Along the Biomedical Value Chain and bridge to Asia




“Thank you and see you in Hong Kong”


**Gregory Rall, Senior Manager
Innovation & Technology**


Email: gregory_rall@hketoberlin.gov.hk



 investhk.gov.hk

 +49(0) 171 3361 237

 gregory_rall@hketoberlin.gov.hk

 Jägerstrasse 33
10117 Berlin
Germany

 INVEST_HK

 e.weibo.com/investhk

 @InvestHK

 www.linkedin.com/company/invest-hong-kong

 www.youtube.com/user/investhk

 www.flickr.com/photos/investhk

InvestHK